ifosfamide has been researched along with Lassitude in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 7.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 6.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue is the most frequent symptom experienced by children/adolescents with cancer." | 5.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| " Measurements included carnitine plasma levels and self-reported fatigue using established child or adolescent fatigue scales and were collected during the 2nd cycle of chemotherapy, and repeated on alternating cycles up to cycle 8." | 3.81 | Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents. ( Hockenberry, MJ; Hooke, MC; McCarthy, K; Taylor, O, 2015) |
| "To examine the influence of the proposed symptom cluster of fatigue, nausea and vomiting, and sleep disturbances on clinical outcomes defined as behavior changes, depression, and performance status in children and adolescents before and after receiving cisplatin, doxorubicin, or ifosfamide chemotherapy." | 3.76 | Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; Krull, K; McCarthy, K; Sambuco, G, 2010) |
| "Ifosfamide is an alkylating agent used in the treatment of germ-cell tumors, sarcomas and lymphomas." | 3.73 | [Ifosfamide induced encephalopathy: 15 observations]. ( Behar, C; Dufour, C; Grill, J; Hartmann, O; Motte, J; Munzer, M; Oberlin, O; Paci, A; Sabouraud, P, 2006) |
| "Ifosfamide and cisplatin cause urinary loss of carnitine, which is a fundamental molecule for energy production in mammalian cells." | 2.70 | Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients. ( Baldelli, AM; Bisonni, R; Canestrari, F; Catalano, V; De Gaetano, A; Ferraro, B; Giordani, P; Graziano, F; Lai, V; Mencarini, E; Rovidati, S; Silva, R; Testa, E, 2002) |
| "Fatigue is the most frequent symptom experienced by children/adolescents with cancer." | 1.35 | Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin. ( Gregurich, M; Hockenberry, MJ; Hooke, MC; McCarthy, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blay, JY | 1 |
| Leahy, MG | 1 |
| Nguyen, BB | 1 |
| Patel, SR | 1 |
| Hohenberger, P | 1 |
| Santoro, A | 1 |
| Staddon, AP | 1 |
| Penel, N | 1 |
| Piperno-Neumann, S | 1 |
| Hendifar, A | 1 |
| Lardelli, P | 1 |
| Nieto, A | 1 |
| Alfaro, V | 1 |
| Chawla, SP | 1 |
| Hooke, MC | 3 |
| McCarthy, K | 3 |
| Taylor, O | 1 |
| Hockenberry, MJ | 3 |
| Gregurich, M | 2 |
| Sambuco, G | 1 |
| Krull, K | 1 |
| Dufour, C | 1 |
| Grill, J | 1 |
| Sabouraud, P | 1 |
| Behar, C | 1 |
| Munzer, M | 1 |
| Motte, J | 1 |
| Oberlin, O | 1 |
| Paci, A | 1 |
| Hartmann, O | 1 |
| Graziano, F | 1 |
| Bisonni, R | 1 |
| Catalano, V | 1 |
| Silva, R | 1 |
| Rovidati, S | 1 |
| Mencarini, E | 1 |
| Ferraro, B | 1 |
| Canestrari, F | 1 |
| Baldelli, AM | 1 |
| De Gaetano, A | 1 |
| Giordani, P | 1 |
| Testa, E | 1 |
| Lai, V | 1 |
| Yoshimoto, J | 1 |
| Nasu, Y | 1 |
| Akagi, T | 1 |
| Obama, T | 1 |
| Tsushima, T | 1 |
| Ozaki, Y | 1 |
| Matsumura, Y | 1 |
| Ohmori, H | 1 |
| Asahi, T | 1 |
| Ohkita, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis) Versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients With Translocation-Related Sarcomas (TRS)[NCT00796120] | Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Sleep in Pediatric Hematopoietic Stem Cell Transplant Patients[NCT04106089] | 50 participants (Actual) | Interventional | 2019-11-18 | Completed | |||
| A Randomised, Double Blinded Cross-over Study Comparing the Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis[NCT01149525] | Phase 3 | 59 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Percentage of participants survived for 6 months from the start of study treatment without progression of disease. Progression of the disease was associated with increasing symptoms, including pain from new or progressing lesions. Delay in disease progression generally represents a clinical benefit to the participant. (NCT00796120)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 66.7 |
| Doxorubicin Plus Ifosfamide | 78.3 |
The DOR is defined as the time from date of first documentation of response (CR or PR, whichever comes first) to the date of documented PD or death. PR=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, CR =Disappearance of all non-target lesions. (NCT00796120)
Timeframe: Up to 20 months
| Intervention | days (Median) |
|---|---|
| Trabectedin | NA |
| Doxorubicin Plus Ifosfamide | NA |
Overall survival defined as time from the date of randomization to the date of death. For participants who were alive at the time of analysis, overall survival was censored at the last contact date. (NCT00796120)
Timeframe: Baseline up to End of Study (an average of 4 years)
| Intervention | months (Median) |
|---|---|
| Trabectedin | 46.6 |
| Doxorubicin Plus Ifosfamide | 33.5 |
Tumor response was assessed according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Partial Response (PR)=at least 30% reduction in the sum of the longest dimensions (LD) of all target lesions in reference to the baseline sum LD, Complete Response (CR) =Disappearance of all non-target lesions. Percentage of participants with objective tumor response was determined by the number of participants with PR or CR divided by the total number of response-evaluable participants. (NCT00796120)
Timeframe: Every 6 weeks during first 9 months of the study and thereafter every 9 weeks up to 20 months
| Intervention | percentage of participants (Number) |
|---|---|
| Trabectedin | 5.9 |
| Doxorubicin Plus Ifosfamide | 27.0 |
The PFS was assessed as median number of days from the date of randomization until the first documented sign of disease progression (increase in disease; radiographic, clinical, or both) or death due to any cause, whichever occurred earlier. (NCT00796120)
Timeframe: Every 6 weeks from randomization during the first 9 months and thereafter, every 9 weeks up to 20 months
| Intervention | months (Median) |
|---|---|
| Trabectedin | 19.6 |
| Doxorubicin Plus Ifosfamide | 8.3 |
2 trials available for ifosfamide and Lassitude
| Article | Year |
|---|---|
Randomised phase III trial of trabectedin versus doxorubicin-based chemotherapy as first-line therapy in translocation-related sarcomas.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Doxorubicin; Drug Adm | 2014 |
Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients.
Topics: Acetylcarnitine; Aged; Antineoplastic Agents; Carnitine; Cisplatin; Fatigue; Female; Humans; Ifosfam | 2002 |
5 other studies available for ifosfamide and Lassitude
| Article | Year |
|---|---|
Fatigue and carnitine levels over multiple cycles of chemotherapy in children and adolescents.
Topics: Adolescent; Antineoplastic Agents; Carnitine; Child; Child, Preschool; Cisplatin; Dose-Response Rela | 2015 |
Carnitine plasma levels and fatigue in children/adolescents receiving cisplatin, ifosfamide, or doxorubicin.
Topics: Adenosine Triphosphate; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot | 2009 |
Symptom clusters in children and adolescents receiving cisplatin, doxorubicin, or ifosfamide.
Topics: Adolescent; Adolescent Behavior; Antineoplastic Agents; Attitude to Health; Child; Child Behavior; C | 2010 |
[Ifosfamide induced encephalopathy: 15 observations].
Topics: Adolescent; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Coma; Enzyme Inhibitors; Fat | 2006 |
[Combination chemotherapy with cisplatin, ifosfamide and adriamycin in patients with advanced transitional cell carcinoma of the urinary tract].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transiti | 1985 |